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ABSTRACT: The concept of the exposome was introduced over
15 years ago to reflect the important role that the environment
exerts on health and disease. While originally viewed as a call-to-
arms to develop more comprehensive exposure assessment
methods applicable at the individual level and throughout the
life course, the scope of the exposome has now expanded to
include the associated biological response. In order to explore
these concepts, a workshop was hosted by the Gunma University
Initiative for Advanced Research (GIAR, Japan) to discuss the
scope of exposomics from an international and multidisciplinary
perspective. This Global Perspective is a summary of the
discussions with emphasis on (1) top-down, bottom-up, and
functional approaches to exposomics, (2) the need for integration
and standardization of LC- and GC-based high-resolution mass spectrometry methods for untargeted exposome analyses, (3) the
design of an exposomics study, (4) the requirement for open science workflows including mass spectral libraries and public
databases, (5) the necessity for large investments in mass spectrometry infrastructure in order to sequence the exposome, and (6)
the role of the exposome in precision medicine and nutrition to create personalized environmental exposure profiles.
Recommendations are made on key issues to encourage continued advancement and cooperation in exposomics.
■ INTRODUCTION
As early as the 18th century, it was demonstrated that
environmental exposures increase risks of chronic human
disease.1 Public awareness for this idea grew in the 1950s when
causal links were reported between smoking and lung cancer.2
Soon afterward, Rachel Carson’s “Silent Spring” raised
concerns about the adverse health consequences of synthetic
organic chemical exposures,3 thus motivating establishment of
the U.S. Environmental Protection Agency (EPA) and many
new funding avenues for research into the occurrence and
health consequences of environmental contaminant exposures.
The Environmental Science and Technology (ES&T) journal has
communicated such research to an international audience since
1969.4 However, while myriad environmental exposures have
since been discoveredof which only a few hundred have
been studied for disease risksthe underlying methods of
exposure assessment and environmental epidemiology have
remained remarkably static. There has been a shift from
occupational studies of workplace exposures to population-
based environmental studies to research on multiple factors
(e.g., age specific vulnerability) and low dose effects. However,
epidemiology studies still tend to focus on single chemicals or
a handful of related chemicals (e.g., phthalates), rather than
real-world mixtures.
Environmental monitoring and human biomonitoring have
historically been hypothesis driven, addressing environmental
contaminants one at a time. Today, thousands of targeted
analytical methods exist for the accurate measurement of
contaminants in biofluids, food, air, drinking water, and soil.
Nonetheless, each method tends to be applied to only a small
number of chemicals having similar properties or structures.5−7
The health risks of single chemical exposures, or the sum of
chemicals within a related chemical class (e.g., polychlorinated
dioxins8), are estimated by comparison of measured levels to
dose−response relationships derived from animal studies,
which are also conducted one chemical at a time. In
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environmental epidemiology, associations between single
chemicals or chemical mixtures are investigated over a wide
range of exposures to strengthen causal inference.9,10 Although
these chemical-by-chemical approaches are valuable for
confirming a priori hypotheses, they are unsuited for
discovering health effects that arise from the vast majority of
still unknown exposures not yet measured in environmental
media or biospecimens. The exposome concept addresses this
issue, in part through more comprehensive or unbiased
exposure measurements; however, because the number of
chemicals we can measure is now so large, studies need to be
designed differently to avoid promoting false positive findings.
The practical limitations of targeted exposure-effect studies
are obvious. A recent review of chemicals in commerce
identified more than 350,000 chemicals that are registered for
production and use.11 The number of synthetic chemicals that
comprise real-world exposures is even greater because
chemicals in commerce may be complex mixtures or contain
isomers and impurities, and many are transformed in humans
or by microbes in the body (i.e., the microbiome) or in the
environment (e.g., methylmercury) to a multitude of
degradation products. Beyond exposure to commercial
chemicals, we breathe, drink, and eat complex mixtures of
pollutants from anthropogenic emissions to air and water, and
even the cooking of food introduces potentially carcinogenic
byproducts.12 In addition, the greatest intake of the chemical
exposome is through diet, a massive contributor to the
exogenous biochemical load, consisting of thousands of natural
or anthropogenic chemicals that impact our endogenous
metabolism and fine-tune risk of diseases.13−15 Natural
substances in food, air, and water may affect health directly16,17
but may also interact with effects posed by environmental
contaminants.18 In addition, environmental exposures to
nonchemical stressors, including noise, light, social, and
socioeconomic factors and green space and climate, affect
biological responses and may also interact with chemical
exposures.19−21 Additional complications arise from variability
in exposures and effects due to changing locations, age,
lifestyle, diet, sex, ethnicity, and health status.22−24
The complex milieu of real-world exposures highlights the
limitations of targeted methods for exploring causes of disease.
Moreover, experimental and observational studies evaluating
adverse effects typically focus on doses or exposures to a single
chemical, which is quite different from those presented by
Figure 1. Functional exposomics approach to study the exposome. In the top-down approach, molecular epidemiology studies focus on exposure
(e.g., small molecule biomarkers of exogenous compounds, protein adducts, reactive metabolites) and biological response profiles (e.g.,
metabolomics, gene expression, methylation) within the host using biospecimens. This approach can generate hypotheses regarding exposure−
disease and exposure−response relationships but does not necessarily capture direct measures of exposure. In the bottom-up approach,
comprehensive data on environmental exposures are collected through surveys, sensors, or trace analytical chemistry in environmental samples
(external exposures) or in biospecimens. This can generate hypotheses on effects but does not necessarily investigate the effect. We propose that a
functional exposomics study bridges these two approaches and consists of the biologically active exposures present in an individual and specifically
examines associations between environmental exposure and biological effect.
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mixtures,25,26 and unmeasured coexposures can confound
results of targeted studies.27,28 Among the largest systematic
human biomonitoring programs in North America and Europe
(NHANES29 and HBM4 EU,30 respectively), only ∼300
chemicals are routinely analyzed by targeted methods in
human biofluids. Moreover, owing to limitations of the sample
volume needed, this list of chemicals has never been measured
collectively in a single individual. Accordingly, cumulative
environmental chemical exposures and their effects are still
poorly understood in population studies.
The “exposome” was first proposed as a research priority
∼15 years ago to recognize the important roles that
environment plays in cancer (and by extension other chronic
diseases).31 The concept was motivated by recognition that the
genome alone explained only a small proportion of the
population variance of chronic disease in developed
countries.32,33 The exposome was intended to represent
everything that the genome did not, and if it could be
adequately characterized in sufficient numbers of people
throughout their life course, it promises to reveal nongenetic
causes of disease and gene−environment interactions (i.e.,
genome × exposome interactions).34−37 Although there has
been a call to “sequence the exposome”,38 there is currently no
agreement as to how this could be accomplished.39 Acquiring
data for all exposures is one obstacle, but linking such data to
health information brings additional challenges. Nonetheless,
the number of publications using the term exposome is
increasing exponentially, and granting agencies are beginning
to provide support for large exposome studies.40−43
In order to discuss the exposome and its collective
challenges, the second International Exposome Symposium
of the Gunma University Initiative for Advanced Research
(GIAR) was organized. Speakers were invited from Europe,
North America, and Japan with a range of expertise in the areas
of medicine, epidemiology, data science, environmental
toxicology, analytical chemistry, and food science (Figure
S1). This article summarizes and integrates the presentations
and subsequent discussions with respect to (1) defining
terminology and the scope of the exposome, (2) consid-
erations in designing exposome studies, (3) characterizing the
exposome via high-resolution mass spectrometry, (4) devel-
oping computational strategies for exposomics data, (5)
producing databases for exposures and exposure-disease
relationships, and (6) predicting roles of exposomics in
precision medicine and precision nutrition.
■ SCOPE OF THE EXPOSOME
For the exposome to achieve widespread adoption, multiple
disciplines will need to work together, including environmental
scientists, social scientists, analytical chemists, molecular
biologists, toxicologists, epidemiologists, and physicians.
Unlike DNA sequencing, where a common technology can
accurately and reproducibly characterize an individual’s
genome, the exposome is highly dynamic in time and space
and requires a range of tools to measure it. Furthermore,
effects of exposure are complicated by the quantal nature of
dose−response relationships within a population, where
individual responses vary with exposure history, age, age at
exposure, genetics, and coexposures. As a result, an individual’s
exposome tends to be defined by the analytical and
methodological approaches used in a given study.20
Since the original conceptualization of the exposome, the
definition has evolved to incorporate omics technologies that
can be harnessed to characterize exposures.44 The exposome
was originally envisioned in 2005 from Dr. Christopher Wild’s
perspective as a cancer epidemiologist as “. . .encompassing
life-course environmental exposures from the prenatal period
onwards”.31 Here, the emphasis was on improving exposure
characterization to find causes of disease that moved beyond
traditional approaches of individual targeted exposures. A few
years later, Rappaport and Smith considered two exposomics
approaches for finding causal human exposures.45,46 The
bottom-up approach that would characterize chemicals in
environmental media (e.g., air, water, diet, the built environ-
ment) and the top-down approach that would focus on
chemicals measured in biospecimens (Figure 1).
More recently, an expansion of the bottom-up definition has
been made to include combinations of external exposure to
chemical, physical, psychological, and social factors. As
comprehensive understanding of bottom-up exposures in-
creases, new and more sophisticated hypotheses can be
developed regarding potential health consequences. Con-
current to advances in analytical chemistry, methods to
measure the external exposome are also expanding. Geospatial
methods to measure indirect exposure include satellite remote
sensing to measure air pollution, human activities, and green
space among other end points.47 Census data can be mined for
neighborhood characteristics. Public databases contain exten-
sive information including crime, infections, environmental
measures, and pesticide application rates, as well as geospatial
data that can be linked to home address, school, or work.48−50
Personal air samplers (passive and active)51−55 can be worn to
monitor bottom-up exposures in the near-field environment,
and smartphone apps or other wearable devices, such as smart
watches, increasingly can be used to “crowd source” measures
of noise, activity, and social factors and link them to
physiologic measures.56 Recent work has even detailed an
integrated pipeline to analyze a full complement of biotic and
abiotic exposures in the personal airborne exposome.57 A great
deal of potential for understanding social networks can be
derived from social media platforms, rendering measures of the
exposome even more robust and helping to identify sources of
variability in the detected endogenous chemicals.
In contrast, the top-down strategy for finding causes of
disease relies on samples of human biospecimens to
simultaneously investigate exposures originating both inside
and outside the body. By employing untargeted omics to
compare exposomes in biospecimens from diseased and
healthy subjects, it is now possible to discover potentially
causal chromatographic features and use them to generate
hypotheses for follow-up studies that confirm their chemical
identities, identify sources of exposure, and establish
exposure−response curves.36,58−60 Since blood is the most
common biospecimen that is archived in prospective-cohort
studies, this top-down strategy led to the concept of the “blood
exposome” and broadened the universe of exposures to include
pollutants, diet, drugs, and endogenous chemicals.17 More
recent definitions of the exposome have been formulated to
include the collection of other omics methodsmetabolomics,
metallomics, adductomics, proteomics, and metagenomics
that can characterize exposures61 and the molecular changes
associated with exposures.60,62−66 Critical to this latter
definition is the notion that a cumulative biological effect
can be used to evaluate overall exposure and allostatic load.60
Incorporating biological responses within a top-down frame-
work enables an understanding of how exposures exert stress
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on host homeostasis, while potentially revealing causal
pathways and mechanisms underlying exposure−disease
relationships. Recent applications of this approach that
combine exposure monitoring with biological response,
where multiple exposures are assessed in individuals and
compared with phenotype or omics profiles, have provided
novel insight into the role of environment in disease risk.36
This is exemplified by linking dietary exposure with various
clinical outcomes and disease risk in an epidemiological setting
using metabolomics-based approaches.67,68 However, while
allostatic load can be estimated, the root causes of these
stressors and the role of exposure timing, route, or source
cannot be captured by a top-down approach and may even be
absent from the analysis, limiting the ability to develop
interventions.
Full characterization of causal exposome features and
subsequent interventions requires knowledge of exposure
sources. This is relatively simple when exposures are measured
bottom-up in external media, such as air, water, or food
(external exposome), but can be more complicated when
measurements are made top-down in biofluids (internal
exposome66). Herein, we propose to further distinguish
measurable components of both approaches for characterizing
the exposome. Accordingly, the exposome can be divided into
the following four categories (Figure 1): Bottom-up: (i)
general external exposures including the built environment,
climate, air pollution, social stressors, socioeconomic factors,
etc. and (ii) specific external exposures such as chemical
contaminants, diet, occupational exposures, or medication.
Top-down: (iii) internalized exogenous exposures that
comprise the fraction of non-nutrient environmental molecules
that have entered the organism and (iv) endogenous nutrient
exposures, including gut microbiota and their associated
metabolites, that arose either directly from the diet or are
products of endogenous metabolism reflecting the exposure
(e.g., lipid peroxidation products from oxidative stress, etc.). A
combination of these four categories provides a framework for
linking external exposure to internal dose, biological response.
and adverse health outcomes, thus defining an individual’s
functional exposome.
While bottom-up and top-down definitions of the exposome
can aid in study design, the greatest potential in the application
of exposomic approaches lies in integrating the top-down
approach with the bottom-up approach. This approach, which
we define here as functional exposomics, has a greater scope
that enables synergy by combining internal measures of
exposure and biological response with measures of the external
environment in order to identify exposure sources, the source
of the biological response, and to better establish disease
causality.69 For example, untargeted high-resolution mass
spectrometry (HRMS) approaches may demonstrate that the
small molecule chemical profiles in biofluids are central in
linking external exposure (i.e., measured as environmental
chemicals of concern in food) to internal dose (i.e., exposure
biomarkers), biological response (measured as alterations in
endogenous metabolic pathways), and disease (through shifts
in metabolism linked to disease pathogenesis). This
information can be linked to source of exposure (e.g., air,
water, diet) to provide a complete understanding of the
relationship between environment/exposome and health or
disease outcome.67,68,70 This has been demonstrated by recent
studies linking occupational exposures to a chlorinated volatile
organic solvent with alterations in both the exogenous and
endogenous metabolome,71 metabolomic phenotypes of
exposure to common traffic-related air pollutants, and
metabolite changes detected in individuals decades after an
initial exposure occurred.71−74 Incorporating measures of
additional omics layers within the exposome enables a
systems−biology framework to study the effects of exposures,
providing, for the first time, the comprehensive character-
ization needed to elucidate potential toxicological mechanisms
at the population level.75 A recent report proposed eight
hallmarks of environmental insult that jointly lay the
foundation for the health consequences of environmental
exposures.76
The current work focuses on the role of small molecules in
the exposome of the type that are generally analyzed in
untargeted metabolomics-based efforts using HRMS. However,
the other “omic” approaches also play an important role in
exposomic science. In particular, integrative “omics” offers the
potential to provide global patterns coupled to metabolic and
physiological dysregulations and capture the biological
complexity associated with exogenous exposures. One omic
technology that has been explored in detail is adductom-
ics,77−79 which has been proven useful for identifying
exposures to exogenous compounds and in newborn blood
spots.64 While beyond the scope of this work, interested
readers are encouraged to explore examples of the applications
of proteomics,80 genomics,81 and epigenetics82 to investigating
the exposome. It is expected that these technologies will
continue to contribute to our understanding of the health
effects of environmental exposure.83
The necessity of exposomics will be further amplified by the
consequences of climate change, with multiple ramifications
for the environment and the ensuing effects upon human
health.84,85 Accordingly, exposomics should be considered an
important component of climate change research. In addition,
although all these approaches are largely discussed from a
human perspective, they can be equivalently applied to other
organisms. For example, the polar bear blood exposome has
been examined to identify the specific chemicals that lead to
thyroid disruption.86 Other laboratory animal models are being
used to simulate human exposome conditions, such as to
combinations of dietary and occupational exposures, but also
to understand aquatic exposomes downstream of municipal
wastewater,87 as well as for real-world applications due to tire
rubber-derived exposure.88 Nonhuman exposome studies will
be important for the protection of wildlife and ecosystems as
recently demonstrated for coho salmon88 and will also protect
humans under the one health paradigm.89,90
■ CONSIDERATIONS IN EXPOSOME STUDY DESIGN
Exposomics is a nascent field with unique data requirements,
thus existing cohorts and ongoing studies may not be optimal
for exposome studies.91 For example, many existing large-scale
metabolomics studies were designed to explore associations
between nutrient metabolites and health outcomes, and
general demographic and disease-specific clinical parameters
were collected with this sole intention. Data on environmental
exposures, or exposure biomarkers, and broader health
conditions are often lacking, and biological samples may not
be of sufficient quality or quantity for comprehensive and
optimal exposomic analyses. An atlas or reference exposome
study has not yet been conducted but is sorely needed. Such a
study would be analogous to efforts in genomics to haplotype
different populations around the world (i.e., the Hapmap).
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Because the exposome will vary by culture, geography, time
(i.e., the 1990s are different from the 2020s) and life stage (an
infant is different from an adult), mapping a reference
exposome will require significant resources, similar to the
Hapmap project. However, the potential benefit to researchers
is enormous because it will enable us to better understand the
role of culture, geography, life stage, and time in predicting the
exposome and improve our interpretation of results enabling
better causal inference. Such a large-scale global project should
be a major priority for researchers and will require substantial
resources and collaboration. With respect to the more typical
exposome study, we propose a suite of guidelines that are
described in the Supporting Information.
■ MEASURING THE CHEMICAL EXPOSOME BY
MASS SPECTROMETRY
There are multiple approaches for data acquisition that should
be considered in comprehensive exposome studies, including
questionnaires, mobile sensors for air quality92 and noise,93 UV
exposure,94 and physical activity,95,96 as well as smartphone
apps to assist with acquisition of dietary data.97 Nevertheless,
given the great potential for making molecular links between
bottom-up and top-down studies, the current discussion
focuses on the application of mass spectrometry for acquiring
the small molecule chemical exposome, with an emphasis on
HRMS acquisition and untargeted data analysis.
Considering the complexity of the chemical exposome, it is
unlikely that there will soon be a single untargeted method
capable of capturing the full range of small molecules that are
present in biofluids or environmental samples.98 In a review of
the human blood exposome by Rappaport et al.,17 the
concentrations of 94 known pollutants, 49 drugs, 195 food
chemicals, and 1223 endogenous chemicals spanned 11 orders
of magnitude in blood, from 160 fM to 140 mM.17
Considering that modern mass spectrometers are at best
linear over 5−6 orders of magnitude, several types of unbiased
sample extractions and untargeted analytical methods will be
required to achieve detection and semiquantification for a
comprehensive profile of small molecules in human blood.98
Untargeted high-resolution metabolomics analysis, based on
liquid chromatography (LC) and HRMS has been proposed
for “sequencing the exposome”,38 but clearly, a wider range of
instrumental approaches will be required. This can be
exemplified by considering the wide range of organic
contaminants routinely monitored in human blood by target
methods (Figure 2). These analytes span approximately 18
orders of magnitude in water solubility and 15 orders of
magnitude in octanol−water partition coefficients. Only half of
these analytes are relatively water soluble and have polar
functional groups that can be ionized under atmospheric
pressure, making them amenable to LC-HRMS workflows. The
other half are relatively nonpolar and semivolatile and are best
analyzed by gas chromatography (GC)-HRMS workflows.
Untargeted GC-HRMS is therefore becoming increasingly
popular as a complement to LC-HRMS, which together enable
a more comprehensive coverage of the small molecule
exposome.99−102 Furthermore, considering that prominent
hydrophobic organic contaminants are preferably analyzed by
GC, and their biotransformation products are only detectable
by LC,103 the combination of both instrumental approaches in
untargeted modes could simultaneously reveal exposure
sources and individual variation in biotransformation capacity.
For truly comprehensive exposure, trace metals in blood
should be analyzed by another method such as inductively
coupled plasma mass spectrometry (ICP-MS).104
HRMS technologies are an essential component for
characterizing the human exposome because of their inherent
sensitivity, dynamic range, and high-frequency full scanning
with high mass accuracy.105,106 The present capabilities of
these instruments to collect full scan MS1 and parallel MS2
data, by data-dependent or data-independent approaches,
opens possibilities to identify known substances through
formula assignment and spectral library matching, with the
additional possibility to annotate and structurally characterize
complex “molecular dark matter”, which constitutes the
Figure 2. Full coverage of the chemical exposome will require multiple instrumental approaches, as shown by the chemical space of 299 internal
exogenous analytes routinely targeted in large population biomonitoring studies in blood or urine. a) Measurement of the analytes will require a
mixture of LC- and GC-based approaches that are b) dependent upon the analyte class. Analytes were selected from the National Health and
Nutrition Examination Survey (1999−2016, latest update in 2019), Centers for Disease Control and Prevention (USA), and HBM4 EU (European
Environment Agency, and European Commission, latest update in 2018). Water solubility and Kow values are estimated from EPA EPI Suite
software and span 18 orders of magnitude for water solubility and 15 orders of magnitude for Kow. Estimations of the Kow values for the anionic
perfluoroalkyl acids included in the class of perfluoroalkyl and polyfluoroalkyl substances are from Hidalgo and Mora-Diez.163
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majority of all HRMS signals in typical samples.107−112 In
addition, the advent of ion mobility technologies can provide
further resolving power for untargeted approaches.113−116
However, critical challenges remain. As described by
Rappaport et al.,17 the abundance of environmental chemicals
in biological samples is, on average, 3 orders of magnitude
lower than endogenous metabolites, drugs, or dietary
components. Thus, going beyond the metabolome into the
exposome necessitates higher sensitivity instruments or
methods. Unbiased sample preparation methods should be
further developed to comprehensively concentrate the trace
small molecule exposome, while minimizing matrix suppres-
sion by highly abundant endogenous metabolites (e.g.,
phospholipids). Although untargeted HRMS data acquisition
strategies are not inherently quantitative (i.e., few internal
standards, lack of external calibration curves for most analytes),
a strategy has been developed and validated that allows
retrospective quantification of analytes discovered in untar-
geted exposome studies. The so-called “reference stand-
ardization protocol” makes use of concurrently analyzed
pooled reference samples and was shown to be comparable
to surrogate standardization or internal standardization.117,118
Sample throughput in HRMS approaches remains an
obstacle to large exposome studies, and this is compounded
here by our recommendations that multiple mass spectrometry
methods should be applied to individual samples. For example,
the Japan Environment and Children’s Study (JECS)119−121
cohort has hundreds of thousands of individual samples, which
may not be feasible for the current state of HRMS without
many dedicated instruments working in parallel. As a reference
point, JECS is currently analyzing 5000−20,000 samples by
mass spectrometry per year for heavy metals, PFASs, and
phthalate metabolites, as well as some insecticides; however,
this throughput is not currently feasible for brominated/
phosphorus flame retardants, dioxins, and some pesticides that
require complex sample preparations. Targeted LC-MS/MS
methods (i.e., with MRM transitions) are becoming more
comprehensive and can be adapted to increase throughput in
exposomics studies. For example, a recent platform was able to
analyze 1000 metabolites or exposome-related compounds
using a triple quadrupole linear ion trap instrument.63
Conversely, it is not always necessary to analyze thousands
of chemicals. Attempts have been made to prioritize chemicals
for exposome-based studies, enabling the development of
targeted quantitative methods suitable for low-abundant
molecules that are difficult to measure with screening
approaches.122
While there is a necessity to increase mass spectrometry
throughput, there is a concomitant need to increase institu-
tional investment in facilities for exposome studies at a scale
that approaches the investments in genome sequencing
technologies. In order to actionize the exposome on the
scale of the Human Genome Project, extensive support will be
required from funders. Concurrent with this investment, there
is a requisite need for method standardization and data
harmonization. A good example of these efforts is the EPA’s
Non-Targeted Analysis Collaborative Trial (ENTACT), which
included nearly 30 laboratories to characterize 10 synthetic
chemical mixtures, three standardized media (human serum,
house dust, and silicone band) extracts, and thousands of
individual substances using GC- and LC-HRMS ap-
proaches.123 While it is not realistic or even desirable for
every laboratory to employ identical methodologies, common
retention indexing in LC and GC approaches, as well as
common reference materials (e.g., NIST SRM1950 for plasma)
could assist in producing data that can be combined across
independent laboratories.124 For example, the concentration of
small molecules could be normalized based on their fold
difference relative to human plasma (NIST SRM1950) or
semiquantified against other common reference materials using
reference standardization.117
A number of existing resources support MS-based
untargeted small molecule profiling and identification,
including open-access software for data preprocessing (e.g.,
MS-DIAL,125 MZmine,126 XCMS127) and compound data-
bases and spectral libraries (e.g., Massbank,128 GNPS,129
HMDB,130 T3DB,131 and PubChemLite132,133), as well as
resources dedicated to cover the exposome and its associated
metabolism (e.g., Exposome-Explorer,134 NORMAN (https://
www.norman-network.com/), and CECscreen135). Confidence
in annotations can be strengthened by using a standardized
retention indexing system. For GC, a robust system already
exists (Kovats retention index, using a series of alkanes), but
for LC, there is currently no widely accepted method for any
mode of chromatography. Efforts have been made to establish
a similar strategy for LC-MS with a series of 2-dimethylami-
noethylamine (DMED)-labeled fatty acids.136 Moreover, new
approaches based on drift time in ion-mobility separation (i.e.,
based on collision cross section) in modern hybrid mass
spectrometers show alternative promise.137,138 Software for
data analysis that can accommodate both LC- and GC-HRMS
chromatograms, while deconvoluting MS2 data, must continue
to be optimized and validated.139 Ideally, the software and
supporting spectral libraries should be vendor neutral (e.g.,
mzXML) to enable experimental replication and to support
open science activities under FAIR data management
principles (findability, accessibility, interoperability, and
reusability). A bottleneck in exposome studies is the structural
characterization of hundreds or thousands of important, yet
unknown, molecular features in human or environmental
samples, but powerful open science tools are increasingly
available that combine untargeted MS1 and MS2 data for high-
throughput structural characterization by molecular network-
ing.140 These resources and approaches, if commonly adopted,
would open the possibility to combine several small exposome
studies into larger and more powerful metastudies.
■ WORKING WITH EXPOSOME DATA
A Call to Create a Comprehensive Exposome Data-
base. There have been a number of initial efforts in exposome
database construction.141,142 The EPA CompTox Chemical
Dashboard, in particular, is an excellent source that currently
contains 882,000 chemicals as of December 2020.143 In
addition, the NORMAN network (http://www.norman-
network.net/) contains extensive information on emerging
substances in the environment, and the recent COlleCtion of
Open Natural prodUcTs (COCONUT) database provides
over 400,000 unique natural products.144 However, the
majority of databases focus on the parent structures of
exposures and lack information on the biological and
microbiota transformation products, which can serve as
internal biomarkers of both exposures and biological processes.
Moreover, the dark matter of the metabolome (known
unknowns112) in the existing databases is largely missing.
Incorporating known unknowns into future methods or data
analysis workflows can be done by sharing suspect lists (e.g.,
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10.5281/zenodo.2656745)145 with associated confidence levels
for compound annotation146 and even proposed structures.
Likewise, the current repositories for food-borne compounds
still lack spectral information essential for identification
purposes, and in general, the biochemical diversity in foods
remains relatively poorly catalogued.147 In the future, this can
be vastly improved by retention index reporting and associated
MS2 spectra. In current databases, various nomenclature
methods are used including IUPAC Name, InChI, InChIKey,
SMILES, CHEBI, and CAS Number. There should be a
common nomenclature and ontology dedicated to exposome
chemicals, and InChIKey might be the best choice because it
facilitates the search and share of chemical information and is
commonly used in most databases due to its fixed length and
format. In order to make it comprehensive, an exposome
database should also include organometallic compounds that
are not routinely analyzed by HRMS-based approaches. With
respect to the analysis, interpretation, and reporting of
exposomic data, we provide additional discussion and details
in the Supporting Information.
■ PRECISION DIAGNOSTICS
A potential future application of exposomics is in the area of
diagnostic tools. The relative transiency of metabolic changes
across individuals may be limiting in this regard, but for
chronic illnesses (i.e., cancer, liver disease), disease specific
signatures have already been described.148,149 A potentially
overlooked area of research is nontraditional biological
matricessuch as skin, hair, or toenails. Medicine has
traditionally focused on blood and urine as the major
biosamples for routine medical monitoring. However, tissues
with slow growth rates may offer complementary findings that
reflect integrated changes in metabolism over time.150−152
While exogenous chemicals can contaminate these tissues,
focusing on endogenous metabolites (e.g., cotinine, cortisol)
has been validated in targeted assays.153,154 Additional research
is needed using nonconventional biological matrices because
they may provide cumulative and/or time varying information
on metabolic changes secondary to disease. Further, given that
the pharmacokinetics of chemicals favor measurement in
different matrices (e.g., hydrophobic chemicals tend to be
better measured in plasma, while hydrophilic chemicals are
better measured in urine), researchers should consider the use
of multiple biomatrix samples in conducting exposomic
studies. For example, the use of both plasma and urine
would increase overall coverage of the exposome compared to
studies that use only a single biomatrix for analysis.
■ PRECISION EXPOSOMICS
One of the most important ways to integrate exposomics into
healthcare is to focus on precision medicine, which is designed
to optimize efficiency, diagnosis, or therapeutic benefit for
particular subgroups of patients. To date, precision medicine
has focused on genetic or molecular (epigenomics, proteomic,
etc.) profiling. However, we know that the environment must
be a driver of patient response to treatment or disease
progression. For example, if lead is neurotoxic, it stands to
reason that exposure to lead will affect the progression of
Alzheimer’s Disease or Autism. Further, we are well aware that
air pollution affects asthma and that smoking will exacerbate
lung and heart disease. Nevertheless, environmental or
exposomic issues are rarely considered in precision medicine
programs. For precision medicine to be truly precise, there is a
clear need to incorporate environmental factors that determine
the variability in treatment effects or disease progression.
Furthermore, because environmental factors are modifiable,
identifying their role in the response to treatment may be
actionable. Therefore, a major driver of exposomics should be
to identify markers of vulnerability and susceptibility that can
be clinically actionable.155 To do this, exposomics must expand
from public health prevention studies (i.e., case control or
longitudinal cohorts of healthy individuals) that address the
environmental causes of disease to clinical studies of patients
to determine how environment impacts existing disease.
Although a seemingly subtle shift in focus, the purpose and
interpretation of clinical research is very different from public
health research. Clinicians may not find causal environmental
factors to be useful in patient care. For example, the clinical
treatment of a 61-year-old man who has a history of smoking
and presents with a lung cancer is not impacted by the
smoking history. Decisions on his care, (e.g., surgery,
chemotherapy, or even hospice) will be made independent
of his smoking history. However, if we begin to measure
exposomic chemical signatures when such patients present, we
may begin to impact such decisions. It is reasonable to
hypothesize that certain signatures predict differential
responses to chemotherapeutic agents, resulting in a need to
modify their dose to reduce the degree of side effects. Further,
as we create better informatic tools to identify the source of
chemical signatures (diet, home environment, behavior,
geography, cultural practices, water/air quality, etc.), we may
be able to alter such signatures toward preferred treatment
phenotypes. In doing so, we become partners in the growing
wave of precision medicine and open the possibility to
understand the gene−environment interactions that are
impacting clinical outcomes. This information can be
combined with data from wearables to provide a digital
phenotype that includes a temporal component necessary for
establishing causality in relation to environmental exposures.
Exposomic studies combined with wearables may be able to
identify previously unknown triggers of disease exacerbation at
the individual level, such as triggers of asthma attacks or
angina. It would be of particular benefit to identify
personalized environmental triggers of disease exacerbation
or progression as well as environmental factors that interfere
with drug treatment. For example, personal environment
sample collecting devices could be carried by individuals with
asthma or chronic lung disease.57 The collected samples could
then be analyzed using mature exposome-based protocols that
measure thousands of small molecules and environmental
chemicals of concern. A more specific example is that of a
metabolomics-based method that monitored real-time ex-
posure to xenobiotics in sweat.156 The data provided
personalized exposure profiles of individuals that can be
coupled to individualized metabolic activities to map the
physiological response to exposure. When coupled with a
symptom diary or, even better, physiologic data such as that
collected by a wearable device,157 we can individualize our
understanding of the triggers of disease exacerbation. When
that is possible, exposomics will then have entered the world of
clinical medicine. Further, by doing so, exposomics and
environmental health will finally be integrated into medical
education, which has been long overdue. As another example, a
targeted approach might include screening for the most
suspect environmental stressors that have already been linked
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to a particular disease. Obesogenic chemical exposures such as
phthalates could be screened in patients with Type 2 diabetes
and linked to measures of insulin resistance (e.g., hemoglobin
A1c) and if exposures are associated with higher glucose; then,
interventions implemented to reduce phthalate exposure could
be made accordingly158 with glucose monitoring to establish
cause and effect of the intervention. The effect of potential
drug−exposome interactions can also be evaluated and
catalogued in databases maintained by health care facilities.159
Personalized nutrition will be an important component of an
exposome-based approach,160,161 and dietary intervention
remains a readily actionable area. In addition to the medical
level, an exposome (i.e., untargeted) approach can also be
applied as a public health prevention measure in communities
that experience clusters of disease, such as cancer. Such a
precision public health initiative could discover chemicals that
may impact disease in the community and develop strategies to
reduce exposure in susceptible patients. Furthermore, a variety
of “omics” platforms can be used to enhance plausibility in the
context of environmental health challenges that may be
contentious and politically sensitive. Support for mechanistic
underpinnings for a charged claim related to social inequities
driving adverse health effects, for example, through unbiased
observation of DNA methylation associated with various levels
of disadvantage, may add value to candidate end point
approaches that can be seen as preordained via prior
observations. As one specific such application, early life family
adversity was shown to be reflected in patterns of DNA
methylation in kindergarten children,162 increasing the call for
interventions to protect youth for such stresses. Given our
increasing understanding of the causal role that environmental
exposures exert in disease etiology, precision exposomics will
become an important component of precision medicine
approaches to personalized healthcare as well as public health
initiatives.
■ CONCLUSION
The exposome concept is maturing and gaining increasing
applications in human and wildlife studies. Significant progress
has been made in multiple areas including the following: (1)
The scope and composition of the exposome has become
clearer. (2) Increased numbers of health researchers have
begun including exposomic risks in etiological research. (3)
The urgency and importance of funding exposome projects has
been acknowledged by governments and funding agencies. (4)
Advanced techniques and methods for characterizing ex-
posures and tools for analyzing complex data sets are more
available. (5) Databases for compiling and sharing exposome
data are evolving quickly. However, there are still multiple
obstacles to actionizing the exposome to directly benefit
patients and contribute to disease prevention. Some critical
challenges include the following: (1) How to untangle the
interactions across exposures and those between exposures and
genomes, microbiomes, and other endogenous factors that
could influence exposure-disease relationships. (2) Replication
and validation of the findings will be needed for better
delineating the causes of human diseases. (3) Statistical and
computational methods will be required to meaningfully
associate the exposome to health outcomes. (4) Methods
will be needed to characterize personal exposome phenotypes
and utilize the information to achieve precision medicine.
These efforts will require the combined endeavors of diverse
stakeholders including basic scientists, clinicians, policy
makers, funders, and the general public to resolve the
challenges. Working together across disciplines, we can
actionize the exposome to increase our understanding of the
etiology of chronic heterogeneous diseases toward the goal of
intervention and future disease prevention.
Key Messages
(1) The exposome is the interplay of environmental
exposure and biological effect. It can be studied top-
down, bottom-up, or by an integrated functional
approach. Each approach contributes new knowledge
and may also lead to sophisticated new hypotheses.
(2) Small molecule profiling by high-resolution mass
spectrometry (HRMS) is a key approach for measuring
external and internal exposures, including exogenous and
endogenous molecules. However, additional efforts to
combine GC- and LC-analytical approaches are needed
for comprehensive exposomic measures.
(3) Large investments in mass spectrometry infrastructure
will be necessary to support human exposome studies on
a scale equivalent to the human genome project. This
should be done in conjunction with activities in support
of method standardization.
(4) Open science workflows and comprehensive public
exposome databases in combination with spectral
libraries of known and known-unknown substances will
accelerate exposome knowledge.
(5) There is a need for significant developments in big data
analysis and informatics approaches in order to establish
causal links between exposure and adverse health
outcomes.
(6) The precision exposome promises to be an important
component of precision medicine and precision public
health.
(7) Strengthening communication between scientists across
disciplines in combination with the development of
interdisciplinary exposomics centers is vital for tackling
the challenge of the exposome.
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